https://www.novartis.com/news/media-releases/novartis-investigational-iptacopan-phase-iii-study-demonstrates-clinically-meaningful-and-highly-statistically-significant-proteinuria-reduction-patients-iga-nephropathy-igan
https://www.biospace.com/article/novartis-pnh-trial-results-put-pressure-on-astrazeneca-s-ultomiris-and-soliris/
https://www.novartis.com/research-development/novartis-pipeline
https://www.biopharmadive.com/news/novartis-iptacopan-pnh-alexion-complement/634793/
https://pharmaphorum.com/news/novartis-oral-drug-iptacopan-tops-injectables-in-head-to-head-pnh-trial
https://seekingalpha.com/article/4566810-novartis-competitors-take-note-iptacopan-is-coming
https://www.fiercebiotech.com/biotech/novartis-eyeing-3b-market-beats-astrazeneca-blockbuster-phase-3-trigger-race-regulators
https://www.clinicaltrialsarena.com/news/novartis-iptacopan-pnh/
https://www.fiercebiotech.com/biotech/novartis-rolls-out-encouraging-phase-2-data-rare-kidney-diseases-little-competition-sight
https://www.clinicaltrialsarena.com/news/novartis-eyes-accelerated-fda-approval-for-iptacopan-across-multiple-indications/
